首页> 美国卫生研究院文献>Oncotarget >Multifunctional targeting daunorubicin plus quinacrine liposomes modified by wheat germ agglutinin and tamoxifen for treating brain glioma and glioma stem cells
【2h】

Multifunctional targeting daunorubicin plus quinacrine liposomes modified by wheat germ agglutinin and tamoxifen for treating brain glioma and glioma stem cells

机译:小麦胚芽凝集素和他莫昔芬修饰的多功能靶向柔红霉素加奎纳克林脂质体用于治疗脑胶质瘤和神经胶质瘤干细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Most anticancer drugs are not able to cross the blood-brain barrier (BBB) effectively while surgery and radiation therapy cannot eradicate brain glioma cells and glioma stem cells (GSCs), hence resulting in poor prognosis with high recurrence rates. In the present study, a kind of multifunctional targeting daunorubicin plus quinacrine liposomes was developed for treating brain glioma and GSCs. Evaluations were performed on in-vitro BBB model, murine glioma cells, GSCs, and GSCs bearing mice. Results showed that the multifunctional targeting daunorubicin plus quinacrine liposomes exhibited evident capabilities in crossing the BBB, in killing glioma cells and GSCs and in diminishing brain glioma in mice. Action mechanism studies indicated that the enhanced efficacy of the multifunctional targeting drugs-loaded liposomes could be due to the following aspects: evading the rapid elimination from blood circulation; crossing the BBB effectively; improving drug uptake by glioma cells and GSCs; down-regulating the overexpressed ABC transporters; inducing apoptosis of GSCs via up-regulating apoptotic receptor/ligand (Fas/Fasl), activating apoptotic enzymes (caspases 8, 9 and 3), activating pro-apoptotic proteins (Bax and Bok), activating tumor suppressor protein (P53) and suppressing anti-apoptotic proteins (Bcl-2 and Mcl-1). In conclusion, the multifunctional targeting daunorubicin plus quinacrine liposomes could be used as a potential therapy for treating brain glioma and GSCs.
机译:大多数抗癌药物不能有效地穿过血脑屏障(BBB),而外科手术和放射疗法则无法根除脑神经胶质瘤细胞和神经胶质瘤干细胞(GSC),因此预后差,复发率高。在本研究中,开发了一种多功能靶向柔红霉素加奎纳克林脂质体的药物,用于治疗脑胶质瘤和GSC。对体外BBB模型,鼠神经胶质瘤细胞,GSC和带有GSC的小鼠进行了评估。结果表明,多功能靶向柔红霉素加奎纳克林脂质体在穿越血脑屏障,杀死神经胶质瘤细胞和GSC以及减少小鼠脑胶质瘤方面显示出明显的能力。作用机制研究表明,多功能靶向药物脂质体的功效增强可能归因于以下几个方面:逃避了血液循环的快速消除;有效地穿越BBB;改善神经胶质瘤细胞和GSC的药物吸收;下调过度表达的ABC转运蛋白;通过上调凋亡受体/配体(Fas / Fasl),激活凋亡酶(胱天蛋白酶8、9和3),激活促凋亡蛋白(Bax和Bok),激活肿瘤抑制蛋白(P53)和抑制GSCs诱导凋亡抗凋亡蛋白(Bcl-2和Mcl-1)。总之,多功能靶向柔红霉素加奎纳克林脂质体可作为治疗脑胶质瘤和GSC的潜在疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号